Prochlorperazine Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization
AAPS PharmSciTech. 2022 Jun 2;23(5):156. doi: 10.1208/s12249-022-02307-8.ABSTRACTSumatriptan succinate and prochlorperazine maleate are a clinically proven combination for treating migraine and associated nausea and vomiting. Classical oral dosage forms are not frequently workable in migraine because of the associated nausea/vomiting, and no effective fixed dose combination is available. Thus, the aim of the study was to optimize a combined sumatriptan-prochlorperazine orodispersible film for rapid release of drugs. Orodispersible films were prepared by solvent casting method using varied amounts of polyvinyl alcohol and g...
Source: AAPS PharmSciTech - June 2, 2022 Category: Drugs & Pharmacology Authors: Sana Javed Amjad Hussain Pervaiz Akhtar Shah Syed Atif Raza Ubaid Ullah Anwer Rahat Shamim Fatima Rasool Muhammad Ahsan Hafiz Nadeem Irfan Bukhari Source Type: research

Perphenazine and prochlorperazine decrease glioblastoma U-87 MG cell migration and invasion: Analysis of the ABCB1 and ABCG2 transporters, E-cadherin, α-tubulin and integrins (α3, α5, and β1) levels
In conclusion, the decrease in migratory and invasive ability following treatment with phenothiazine derivatives due to the increase in ABCG2 and E-cadherin expression, and decrease in α-tubulin and integrins expression, may suggest that research on perphenazine and prochlorperazine in the treatment of glioblastoma is worth continuing.PMID:35527777 | PMC:PMC9073583 | DOI:10.3892/ol.2022.13302 (Source: Oncology Letters)
Source: Oncology Letters - May 9, 2022 Category: Cancer & Oncology Authors: Micha ł Otręba Jerzy Stojko Agata Kaba ła-Dzik Anna Rzepecka-Stojko Source Type: research

Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration
In this study, 23 hub genes (IFI6, PLSCR1, XAF1, IFI16, IFI44, MX1, IFI44L, IFIT3, IFIT2, IFI27, DDX58, EIF2AK2, IFITM1, RTP4, IFITM3, TRIM22, PARP12, IFIH1, OAS1, HERC6, RSAD2, DDX60, and MX2) were identified through bioinformatics and network analysis and are closely related to interferon production and function. Interestingly, immune cell infiltration analysis and correlation analysis demonstrate a positive correlation between the expression of 23 hub genes and monocyte infiltration in glomeruli and M2 macrophage infiltration in the tubulointerstitium of LN patients. Additionally, the CTD database, DsigDB database, and ...
Source: Cell Research - May 3, 2022 Category: Cytology Authors: Jianbo Qing Wenzhu Song Lingling Tian Sonia Biju Samuel Yafeng Li Source Type: research

Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration
In this study, 23 hub genes (IFI6, PLSCR1, XAF1, IFI16, IFI44, MX1, IFI44L, IFIT3, IFIT2, IFI27, DDX58, EIF2AK2, IFITM1, RTP4, IFITM3, TRIM22, PARP12, IFIH1, OAS1, HERC6, RSAD2, DDX60, and MX2) were identified through bioinformatics and network analysis and are closely related to interferon production and function. Interestingly, immune cell infiltration analysis and correlation analysis demonstrate a positive correlation between the expression of 23 hub genes and monocyte infiltration in glomeruli and M2 macrophage infiltration in the tubulointerstitium of LN patients. Additionally, the CTD database, DsigDB database, and ...
Source: Biomed Res - May 3, 2022 Category: Research Authors: Jianbo Qing Wenzhu Song Lingling Tian Sonia Biju Samuel Yafeng Li Source Type: research

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics
Major bleeding risks associated with non-vitamin K oral anticoagulants (NOACs) used with and without concurrent antipsychotics in patients with non-valvular atrial fibrillation (AF) were assessed. A total of 98,863 patients with non-valvular AF receiving at least one NOAC prescription from Taiwan’s National Health Insurance database were enrolled. Major bleeding was defined as a primary diagnosis of intracranial or gastrointestinal hemorrhage or bleeding at other sites. The adjusted incidence rate difference (AIRD) per 1,000 person-years and adjusted rate ratio of major bleeding were estimated using Poisson regression an...
Source: Frontiers in Pharmacology - April 14, 2022 Category: Drugs & Pharmacology Source Type: research

Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial
This study randomises forty patients (1:1) to receive either eptinezumab or an infusion of intravenous lignocaine for up to 5 days. It will assess the effect of eptinezumab compared with intravenous lignocaine in aborting status migrainosus, with the primary outcome of time from infusion until resolution of pain. It will explore several secondary measures including change in health resource utilisation, effect on patient reported outcomes of migraine disability and the safety and tolerability of each medication. Ethics and dissemination This study has been reviewed and approved by the Human Research Ethics Committee of Al...
Source: BMJ Open - March 8, 2022 Category: General Medicine Authors: Ray, J. C., Chen, Z., Ramsay, G., Germaine, J., Hutton, E. J. Tags: Open access, Neurology Source Type: research

Migraine in the Emergency Department: A Prospective Multinational Study of Patient Characteristics, Management, and Outcomes
Conclusions: This study suggests that therapeutic practices are not congruent with current guidelines, especially for patients with severe symptoms. Efforts to improve and sustain compliance with existing management best practices are required.Neuroepidemiology (Source: Neuroepidemiology)
Source: Neuroepidemiology - January 12, 2022 Category: Epidemiology Source Type: research

Second-line interventions for migraine in the emergency department: A narrative review
CONCLUSIONS: There are no evidence-based second-line treatments of migraine in the ED setting. For patients with migraine, who fail to improve after treatment with a first-line medication, it is reasonable to use an intravenous NSAID or intravenous acetaminophen. Alternatively, clinicians adept at performing a GONB may offer this treatment.PMID:34806767 | DOI:10.1111/head.14239 (Source: Headache)
Source: Headache - November 22, 2021 Category: Neurology Authors: Farnam Kazi Mallika Manyapu Maha Fakherddine Kumelachew Mekuria Benjamin W Friedman Source Type: research